Patents Assigned to Athera Biotechnologies AB
-
Patent number: 10752680Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.Type: GrantFiled: May 9, 2016Date of Patent: August 25, 2020Assignee: ATHERA BIOTECHNOLOGIES ABInventor: Johan Frostegård
-
Patent number: 10669332Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.Type: GrantFiled: May 9, 2016Date of Patent: June 2, 2020Assignee: ATHERA BIOTECHNOLOGIES ABInventor: Johan Frostegård
-
Patent number: 10222382Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.Type: GrantFiled: January 15, 2014Date of Patent: March 5, 2019Assignee: ATHERA BIOTECHNOLOGIES ABInventors: Ulf De Faire, Johan Frostegård
-
Patent number: 9803028Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21Type: GrantFiled: August 8, 2012Date of Patent: October 31, 2017Assignees: ATHERA BIOTECHNOLOGIES AB, DYAX CORP.Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Patent number: 9796786Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.Type: GrantFiled: August 8, 2012Date of Patent: October 24, 2017Assignees: ATHERA BIOTECHNOLOGIES AB, DYAX CORP.Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20160131661Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.Type: ApplicationFiled: November 6, 2015Publication date: May 12, 2016Applicant: Athera Biotechnologies ABInventors: Ulf DE FAIRE, Johan FROSTEGÅRD
-
Publication number: 20140193413Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.Type: ApplicationFiled: August 8, 2012Publication date: July 10, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20140186360Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.Type: ApplicationFiled: January 15, 2014Publication date: July 3, 2014Applicant: ATHERA BIOTECHNOLOGIES ABInventors: Ulf DE FAIRE, Johan FROSTEGÅRD
-
Publication number: 20140178410Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21Type: ApplicationFiled: August 8, 2012Publication date: June 26, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20130309696Abstract: The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphorylcholine conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof.Type: ApplicationFiled: March 19, 2013Publication date: November 21, 2013Applicant: Athera Biotechnologies ABInventor: Athera Biotechnologies AB
-
Patent number: 8012483Abstract: IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure >95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high autoantibodies particularly high IgM autoantibodies, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM autoantibodies, against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases.Type: GrantFiled: April 15, 2005Date of Patent: September 6, 2011Assignee: Athera Biotechnologies ABInventors: Ulf De Faire, Johan Frostegård
-
Publication number: 20110206679Abstract: The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphoryl-choline conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof.Type: ApplicationFiled: July 3, 2009Publication date: August 25, 2011Applicant: ATHERA BIOTECHNOLOGIES ABInventors: Johan Frostegard, Ulf De Faire, Nancy Pedersen
-
Publication number: 20100278836Abstract: Low levels of antibodies reactive with a PAF-conjugate are related to an increased risk of developing cardiovascular diseases. Thus, compositions and methods of diagnosis and therapy for cardiovascular diseases are provided.Type: ApplicationFiled: October 29, 2008Publication date: November 4, 2010Applicant: ATHERA BIOTECHNOLOGIES ABInventors: Hans Grönlund, Johan Frostegard, Ingrid Dahlbom
-
Patent number: 7662577Abstract: A method of and kit for diagnosing cardiovascular disease in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.Type: GrantFiled: April 1, 2004Date of Patent: February 16, 2010Assignee: Athera Biotechnologies ABInventor: Johan Frostegard
-
Publication number: 20040185514Abstract: A method of and kit for diagnosing cardiovascular disease in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.Type: ApplicationFiled: April 1, 2004Publication date: September 23, 2004Applicant: Athera Biotechnologies ABInventor: Johan Frostegard
-
Publication number: 20040185516Abstract: A kit for diagnosing cardiovascular disease and increased levels of early atherosclerosis in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.Type: ApplicationFiled: April 1, 2004Publication date: September 23, 2004Applicant: Athera Biotechnologies ABInventor: Johan Frostegard
-
Publication number: 20040185515Abstract: A method of and a kit for diagnosing spontaneous abortion involves assessing in a human the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.Type: ApplicationFiled: April 1, 2004Publication date: September 23, 2004Applicant: Athera Biotechnologies ABInventor: Johan Frostegard
-
Patent number: 6780605Abstract: The present invention provides a method of diagnosing cardiovascular disease and increased risk of early atherosclerosis in a human wherein the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of said human is assessed. The present invention further provides a kit carrying out said method.Type: GrantFiled: April 6, 2001Date of Patent: August 24, 2004Assignee: Athera Biotechnologies ABInventor: Johan Frostegärd